Department of Oncology and the Thoracic Oncology, Johns Hopkins Sidney Kimmel Cancer Center, Baltimore, Maryland, USA.
Department of Internal Medicine, University of Missouri-Kansas City, Kansas City, Missouri, USA.
J Immunother Cancer. 2021 Jun;9(6). doi: 10.1136/jitc-2021-002435.
Immune checkpoint inhibitors (ICIs) are the standard of care for the treatment of several cancers. While these immunotherapies have improved patient outcomes in many clinical settings, they bring accompanying risks of toxicity, specifically immune-related adverse events (irAEs). There is a need for clear, effective guidelines for the management of irAEs during ICI treatment, motivating the Society for Immunotherapy of Cancer (SITC) to convene an expert panel to develop a clinical practice guideline. The panel discussed the recognition and management of single and combination ICI irAEs and ultimately developed evidence- and consensus-based recommendations to assist medical professionals in clinical decision-making and to improve outcomes for patients.
免疫检查点抑制剂（ICIs）是治疗多种癌症的标准治疗方法。虽然这些免疫疗法在许多临床环境中改善了患者的预后，但它们也带来了伴随的毒性风险，特别是免疫相关不良事件（irAEs）。为了在 ICI 治疗期间管理 irAEs，需要明确、有效的指南，这促使癌症免疫治疗学会（SITC）召集一个专家小组制定临床实践指南。专家组讨论了单一和联合 ICI irAEs 的识别和管理，最终制定了基于证据和共识的建议，以协助医疗专业人员进行临床决策，并改善患者的预后。
